Joaquín Arribas Lab
Basic/translational research
Hospital del Mar Research Institute (IMIM)
·Barcelona ·

The activity of the research group led by Dr. Joaquín Arribas focuses on the development of new immunotherapies against cancer and on studying the mechanisms of resistance to targeted therapies. To this end, the group has multiple tools at its disposal, including murine models derived from cancer patients. The use of these models allows the entire translation process to be carried out, from the identification of the altered target, the development and preclinical study of the efficacy of the new therapy, to the evaluation of the possible resistance mechanisms developed by the tumor against the new drug.

The three main lines of research are:


  • Immune redirection against solid tumors: development of strategies based on chimeric antigen receptors (CARs).
  • Resistance to immune redirection: study of the molecular mechanisms associated with the resistances that develop in response to immunotherapies and their possible solutions.
  • Immune redirection and senescence: study of the molecular mechanisms involved in the interaction between senescence and tumor progression, mainly mediated by its effect on the immune system.

Main publications in pancreatic cancer:

  1.  Pellegrino B, Herencia-Ropero A, Llop-Guevara A, et al. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409.
  2. Bilal F, Arenas EJ, Pedersen K, et al. The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. Cancer Res. 2021 Jul 15;81(14):3849-3861. doi: 10.1158/0008-5472.CAN-20-4263.
  3. Massó-Vallés D, Jauset T, Serrano E, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15;75(8):1675-81. doi: 10.1158/0008-5472.CAN-14-2852.
Joaquín Arribas López

Principal Investigator

Group members

  • Joaquín Arribas López

Other groups